How to Help Your Patients Find Apremilast in Stock: A Provider's Guide

Your Patients Need Apremilast — Here's How to Get It to Them

You've made the clinical decision to prescribe Apremilast (Otezla or Otezla XR). Your patient is on board. Now comes the part that shouldn't be this hard: actually getting the medication into their hands.

As a prescriber, you know that Apremilast access challenges aren't about supply — they're about the system. Specialty pharmacy routing, prior authorization hurdles, and cost barriers create friction that can delay treatment by days or weeks. This guide provides a practical, step-by-step approach to minimizing those delays for your patients.

Current Availability of Apremilast

As of 2026, Apremilast has no FDA-reported supply shortage. Amgen continues to manufacture and distribute Otezla and the newer Otezla XR (75 mg extended-release, once-daily dosing) through standard specialty pharmacy channels.

The access challenges your patients face include:

• Specialty pharmacy-only distribution: Not available at retail pharmacies
• Near-universal prior authorization requirements
• Step therapy mandates on most formularies
• High out-of-pocket costs ($5,000-$6,800/month without coverage)
• No U.S. generic until approximately 2028-2029

For a comprehensive overview of the current landscape, see our provider briefing on Apremilast in 2026.

Why Patients Can't Find Apremilast

When patients report difficulty finding Apremilast, the issue typically falls into one of these categories:

1. Prescription Sent to a Retail Pharmacy

The most common and most preventable issue. If the prescription is sent to CVS, Walgreens, or another retail pharmacy, it will need to be transferred to a specialty pharmacy — adding days to an already slow process.

2. Prior Authorization Not Initiated

Some workflows assume the specialty pharmacy will identify the PA need and notify the prescriber. This creates unnecessary delays. Initiating PA at the point of prescribing eliminates this bottleneck.

3. Insurance Denial Without Appeal

Initial PA denials are common — but many patients and practices accept the denial without pursuing an appeal. Peer-to-peer reviews and documented appeals overturn a significant percentage of denials.

4. Cost Shock

Even with insurance, patients may face specialty-tier copays of several hundred dollars per month. Without financial support, they may abandon the prescription entirely.

5. Refill Gaps

Patients who don't plan ahead for specialty pharmacy processing times (3-7 business days) may experience treatment interruptions.

What Providers Can Do: 5 Steps to Streamline Access

Step 1: Send the Prescription to the Right Place

Always route Apremilast prescriptions directly to a specialty pharmacy. Common options include:

• Accredo (Express Scripts)
• CVS Specialty
• OptumRx Specialty
• AllianceRx Walgreens Pharmacy
• Biologics by McKesson

Check the patient's insurance to identify their preferred specialty pharmacy. Using an in-network specialty pharmacy reduces processing time and out-of-pocket costs.

Step 2: Submit Prior Authorization at the Point of Prescribing

Don't wait for the specialty pharmacy to flag the PA requirement. Submit the PA simultaneously with the prescription. Key elements for a strong PA submission:

• Documented diagnosis with ICD-10 code
• Prior treatment history (especially if step therapy is required)
• Clinical rationale for Apremilast specifically
• Relevant clinical notes or PASI/BSA scores for psoriasis

Use electronic prior authorization (ePA) through your EHR when available — it's typically faster than fax-based submissions.

Step 3: Enroll the Patient in Amgen SupportPlus

At the point of prescribing, complete the Otezla START Form and enroll the patient in Amgen SupportPlus. This triggers:

• Co-Pay Program: Commercially insured patients may pay $0
• Bridge to Commercial Coverage: Free medication for up to 12 fills while PA is pending
• Safety Net Foundation: Free medication for qualifying uninsured/underinsured patients
• Insurance navigation support from Amgen representatives

Contact: 1-833-44AMGEN (1-833-442-6436)

Step 4: Prepare for Denials and Appeals

Have a standardized appeal workflow ready. When a PA is denied:

1. Request the specific denial reason from the payer
2. Prepare a letter of medical necessity addressing the denial criteria
3. Include documentation of step therapy failures if applicable
4. Request a peer-to-peer review — speaking directly with the payer's medical director often resolves denials
5. Set a timeline: most appeals must be filed within 30-60 days of denial

Step 5: Bridge the Gap with Samples

Keep Otezla starter pack samples in your office. When a patient is starting Apremilast and waiting for specialty pharmacy fulfillment or PA approval, samples ensure they can begin treatment immediately without a gap in care.

Alternatives When Access Fails

If a patient cannot access Apremilast despite support interventions, consider these alternatives based on clinical scenario:

For Plaque Psoriasis

• Methotrexate: First-line oral systemic, generic, ~$15-$30/month. Requires lab monitoring.
• Deucravacitinib (Sotyktu): Oral TYK2 inhibitor, once daily. Potentially more effective than Apremilast for skin clearance. No lab monitoring required.
• Biologics: Adalimumab biosimilars, secukinumab, or IL-23 inhibitors for moderate-to-severe disease.

For Psoriatic Arthritis

• Methotrexate: Standard first-line DMARD
• TNF inhibitors: Adalimumab biosimilars offer strong evidence for both skin and joint disease
• IL-17 inhibitors: Secukinumab, ixekizumab
• JAK inhibitors: Tofacitinib (with appropriate risk assessment)

For detailed comparison, see Alternatives to Apremilast.

Workflow Tips for Your Practice

Build a Specialty Medication Workflow

Create a standardized process for all specialty medications in your practice:

1. Prescribe + submit PA + enroll in manufacturer support — all in the same visit
2. Designate a staff member as the specialty pharmacy liaison who tracks orders and follows up on PAs
3. Use PA tracking tools in your EHR or practice management system
4. Schedule a follow-up contact 5-7 days post-prescribing to confirm the patient received medication

Use Medfinder for Providers

Medfinder's provider platform allows you to check pharmacy availability for Apremilast and other specialty medications. This is particularly useful when:

• A patient needs to switch specialty pharmacies
• You're troubleshooting access issues
• You want to verify stock before sending a prescription

Educate Your Patients

Set expectations at the point of prescribing:

• Apremilast comes from a specialty pharmacy, not their regular pharmacy
• Initial fulfillment may take 5-10 business days
• They may receive a call from the specialty pharmacy for intake
• Financial support is available — share Amgen SupportPlus contact info
• They should plan refills 7-10 days in advance

Patient-facing resources to share:

• How to find Apremilast in stock
• How to save money on Apremilast
• Apremilast side effects: what to expect

Final Thoughts

Getting Apremilast to your patients requires more coordination than it should — but with a streamlined workflow, proactive PA management, and manufacturer support programs, you can significantly reduce access delays. Start by prescribing directly to the patient's preferred specialty pharmacy, submitting PA simultaneously, and enrolling every patient in Amgen SupportPlus at the point of care.

For additional provider resources and real-time availability information, visit Medfinder for Providers.